fbpx

Call now: 07 5408 0900

CEC-013/CEL (Symptomatic)

A phase II, double-blind, randomised, placebo-controlled trial.

Study Title

A phase II, double-blind, randomised, placebo-controlled trial to evaluate the efficacy and tolerability of ZED1227 in celiac disease subjects experiencing symptoms despite gluten-free diet.

Purpose of Study

The objective of this CEC-013/CEL study is the efficacy and tolerability of a 12-week treatment with ZED1227 TID up to a total dose of 75 mg/day, in subjects with treated celiac disease still experiencing symptoms.

Eligibility

You may be eligible for the study if you meet the following criteria.

How long will this study take?

If eligible for the study, your participation is expected to last approximately 19 weeks.


Please contact CDH Research Institute on 07 5408 0900 for additional information or use the email link below. You can also share details of this study to social media via the links below?

Facebook
Twitter
LinkedIn
Pinterest
Email
CDH Research Institute

Complete the form to register.

CDH Research Institute

Complete the form to register.